NEW YORK, February 27, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Moments ago, Analysts Review released new research updates concerning several important developing situations including Acorda (NASDAQ: ACOR), EnteroMedics (NASDAQ: ETRM), Escalon (NASDAQ: ESMC), Fonar (NASDAQ: FONR), and Imris (NASDAQ: IMRS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA(R) research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

ACOR Research Report: ( http://get.analystsreview.com/pdf/?c=Acorda&d=27-Feb-2015&s=ACOR [http://get.analystsreview.com/pdf/?c=EndoStim&d=27-Feb-2015&s=ACOR ] ),

ETRM Research Report: ( http://get.analystsreview.com/pdf/?c=EnteroMedics&d=27-Feb-2015&s=ETRM ),

ESMC Research Report: ( http://get.analystsreview.com/pdf/?c=Escalon&d=27-Feb-2015&s=ESMC ),

FONR Research Report: ( http://get.analystsreview.com/pdf/?c=Fonar&d=27-Feb-2015&s=FONR ),

IMRS Research Report: ( http://get.analystsreview.com/pdf/?c=Imris&d=27-Feb-2015&s=IMRS ).

============

--

Analyst Update: Financial Results andCollaboration

Reviewed by: Rohit Tuli, CFA(R)

Global equities dipped on Thursday as investor enthusiasm was dampened by a pullback in oil prices related to rising inventories, while the dollar rose as economic data drove expectations that the Federal Reserve will raise interest rates. In the U.S., consumer prices fell in the 12 months through January, the first such decline since 2009 as gasoline prices continued to tumble. The S&P 500 ended down 0.15% to 2110.74, Dow was down 0.06% to 18214.42, while Nasdaq was a bright spot in U.S. equities, rising 0.42% to 4987.89 on news of a technology deal. The pan-European Euro Stoxx 600 Index closed up 0.9% higher as investors reacted to a raft of corporate earnings and fresh economic data. The latest GDP data from Spain and UK confirmed a year on year growth of 2% and 2.7%, respectively in the last quarter. The German unemployment rate also stayed at a record low in February. In Asia, Japanese shares outperformed the region by reaching a new multiyear high, but the rest of Asia traded mixed on Thursday.

Acorda Therapeutics Inc's (Acorda) GAAP net income for full-year 2014 was $17.7 million or $0.42 per diluted share, higher from $16.4 million, or $0.39 per diluted share reported in 2013. Non-GAAP net income for the year increased to $73.8 million, up 40.8%. For full-year 2015, the Company anticipates R&D expenses (excluding share-based compensation) to be between $150 and $160 million.

The developer of medical devices - EnteroMedics Inc. (EnteroMedics) reported net loss of $26.1 million, or $0.39 per share for full-year 2014 and a net loss of $6.2 million, or $0.09 per share for Q4 2014. Q4 2014 total operating expenses were $6.0 million, which comprised of research and development expenses of $3.0 million and selling, general and administrative expenses of $3.1 million.

Escalon Medical Corp. (Escalon) reported that its consolidated product revenue for Q2 FY 2015 increased 19.4% YoY to $3.7 million, fuelled by an increase in sales of its Sonomed Escalon Digital Imaging products, Axis management systems as well as an increase in the sales of the Company's Ultrasound and surgical products.

The Inventor of MR Scanning(TM) - Fonar Corporation's (Fonar) net income in the second quarter of fiscal 2015 increased 13% YoY to $3.5 million while the same for H1 FY 2015 increased 0.6% YoY to $6.7 million. Diluted net income per common share available to common shareholders for the second quarter of fiscal 2015 was $0.40, up 21.2% YoY.

Imris Inc (Imris) announced its collaboration with Siemens Healthcare to integrate a VISIUS Surgical Theatre with intraoperative MRI (iMRI) in four hybrid operating suites that the latter recently sold to Sahlgrenska University Hospital.

--

About Analysts Review

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA(R). An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review